New methods for RWE collection and synthesis

Welcome to GetReal

IMI GetReal

Launched in October 2013, GetReal is a three-year project of the Innovative Medicines Initiative (IMI), a EU public-private consortium consisting of pharmaceutical companies, academia, HTA agencies and regulators (e.g., NICE, HAS, EMA and ZIN), patient organisations and SMEs.

GetReal aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process. The consortium is doing this by:

  • Bringing together healthcare decision makers, academics, pharmaceutical companies, clinicians, and other societal stakeholders;
  • Assessing existing processes, methodologies, and key research issues;
  • Proposing innovative trial designs and assessing the value of information;
  • Proposing and testing innovative analytical and predictive modelling approaches;
  • Assessing operational challenges and proposing and testing the impact of solutions;
  • Creating new decision making support, and building tools to allow for the evaluation of development programmes and use in the assessment of the value of introducing new treatments;
  • Sharing and discussing deliverables with healthcare decision makers, academics, pharmaceutical companies, clinicians, and other societal stakeholders;
  • Developing training for researchers, healthcare decision makers and societal stakeholders in the public and private sector in order to increase knowledge about various aspects of effectiveness.

Latest News Latest News

5th Annual Real World Evidence Europe 2017 - 25-26 April, Amsterdam

Posted on March 13, 2017 15:24
Chris Chinn (Sanofi) and Rob Thwaites (Takeda) wil...  

Real-World Evidence Navigator online

Posted on March 09, 2017 09:28
On 8 March 2017, the IMI GetReal project hosted a ...  

Pilot LU5 for the GetReal online course ‘Real-World Evidence in Medicine Development’ - 3 March, 2017

Posted on February 16, 2017 12:44
Friday 3 March 2017, WP5 will run a pilot of Learn...  

Funding Funding


     


The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no [115546], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.